-

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

Company to host conference call and webcast on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 4, 2026, at 4:30 p.m. Eastern Time.

The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived for approximately 90 days. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

Contacts

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

NASDAQ:ACAD

Release Versions

Contacts

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com

More News From Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) during an oral presentation at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston. Building on previously announced topline results, new analyses provided further evidence of a consistent efficacy signal with once...

Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE® STIX (trofinetide) powder for oral solution in Japan for the treatment of Rett syndrome. Under the terms of the agreement, KYORIN will be responsible for leading the commercialization of DAYBUE STIX in Japan and the related regulatory activities on behalf of Acad...

Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware’s May 2025 decision upholding Acadia’s U.S. Patent No. 11,452,721 (the ‘721 patent), which covers the NUPLAZID® (pimavanserin) 34 mg capsule formulation. “We continue to believe in the strength of our position on the NUPLAZID formulation patent, on which t...
Back to Newsroom